We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Is First to Announce FDA Biosimilar Application on Amgen’s Neupogen
Sandoz Is First to Announce FDA Biosimilar Application on Amgen’s Neupogen
Sandoz has become the first drugmaker to announce FDA acceptance of a biosimilar application with its cancer treatment filgrastim, a milestone that indicates the highly anticipated class of products may soon come to market more than four years after Congress approved a regulatory pathway.